LL-37 vs KPV
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Also: Lys-Pro-Val, Alpha-MSH fragment
A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- LL-37 has stronger research evidence (Human Trials) compared to KPV (Animal Studies).
Detailed Comparison
| Attribute | LL-37 | KPV |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. | KPV retains the anti-inflammatory properties of α-MSH without melanocortin receptor activation. It inhibits inflammatory pathways including NF-κB, reduces pro-inflammatory cytokines, and has antimicrobial properties. |
| Common Dosing | 100-200 mcg daily Once daily | 200-500 mcg daily 1-2x daily |
| Administration | Subcutaneous injection or topical | Subcutaneous injection or oral (capsules) |
| Typical Duration | Variable by protocol | 4-8 weeks typical |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. | Studies show effectiveness in inflammatory bowel disease models. Research demonstrates wound healing acceleration and antimicrobial activity. Being investigated for gut health and inflammatory conditions. |
Frequently Asked Questions: LL-37 vs KPV
What is the difference between LL-37 and KPV?
LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. KPV is a immune peptide that a tripeptide derived from alpha-melanocyte stimulating hormone (α-msh). known for potent anti-inflammatory effects, particularly in the gut. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or KPV?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while KPV is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and KPV be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and KPV together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of LL-37 and KPV is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.